CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

660 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BVHLMutationPrognosticSupportsBetter OutcomeClear Cell Renal Cell CarcinomaPatard et al., 2008
CVHLR200W (c.598C>T)PredictiveSupportsSensitivity/ResponseChuvash PolycythemiaRuxolitinibZhou et al., 2016
CVHLA149S (c.445G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseAtuk et al., 1998
CVHLExon 1-3 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
BVHLMutationPredictiveDoes Not SupportSensitivity/ResponseRenal Cell CarcinomaAnti-VEGF Monoclonal AntibodyKim et al., 2017
CVHLE46* (c.136G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLE52K (c.154G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseDollfus et al., 2002
CVHLT157I (c.470C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLR161Q (c.482G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLV62Cfs*5 (c.180del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLQ73* (c.217C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLF76del (c.227_229del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLP86fs (c.254_255insC)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLP86L (c.257C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLS111FS (c.331delA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLS111R (c.333C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLY112* (c.336C>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLL158P (c.473T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLV166D (c.497T>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLN78S (c.233A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL116V (c.346C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLV166F (c.496G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
CVHLR167Q (c.500G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
CVHLN78H (c.232A>C)PredisposingSupportsPredispositionRenal Cell CarcinomaOng et al., 2007
CVHLQ132P (c.395A>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLQ164R (c.491A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLQ195* (c.583C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLQ73* (c.217C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL118P (c.353T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL128R (c.383T>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL153fs (c.457delC)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL158V (c.472C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL169P (c.506T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL178R (c.533T>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLL178P (c.533T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLM54fs (c.161dup)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLF136S (c.407T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLF91* (c.272_273delinsAA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLP59fs (c.176delC)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLP86R (c.257C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLP86L (c.257C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLP86S (c.256C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLS65P (c.193T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLS72P (c.214T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLS72fs (c.214del)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLR176fs (c.526del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLV155E (c.464T>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOng et al., 2007
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseOlschwang et al., 1998
BVHLMutationPredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaEverolimusPowles et al., 2016
Page 1 of 14
Next